TDP-43 Boosts Allergen-Driven Inflammation and Influenza A Replication in Airways

A new study in Nature Communications reports that TDP-43, a well-known RNA-binding protein best studied in neurodegeneration, can also act as a driver of respiratory disease. Researchers focused on airway epithelial cells, where immune signaling and viral defense determine whether inhaled allergens and respiratory viruses escalate into serious inflammation.

Using mechanistic experiments in cultured airway epithelium, the team found that TDP-43 enhances allergen-triggered inflammatory responses. Compared with controls, cells with increased TDP-43 showed amplified cytokine and chemokine outputs, indicating a heightened pro-inflammatory state rather than a generalized stress effect.

The work further connects this inflammatory wiring to viral growth. When influenza A virus was introduced, epithelial cells with elevated TDP-43 supported greater viral replication than cells with reduced TDP-43 activity. The results suggest that TDP-43 does not merely correlate with disease; it actively shapes the host environment that influenza exploits.

To separate allergic inflammation from antiviral immunity, the authors examined signaling pathways associated with innate responses. Their data point to TDP-43 functioning upstream of key inflammatory transcriptional programs, helping explain how allergen exposure can prime the airway for subsequent infection.

The study also emphasizes how RNA regulatory proteins can influence both immune signaling and pathogen permissiveness. Because airway epithelium is the first barrier against airborne threats, changes in RNA handling and stress granule–related biology may shift the balance between effective interferon responses and permissive replication.

Importantly, the findings were not limited to a single stimulus context. Allergens and influenza cooperated in a way that increased detrimental inflammatory activity, consistent with a model in which TDP-43 creates an airway “feed-forward” loop.

From a translational standpoint, the results highlight TDP-43 as a potential target for interventions aimed at patients who experience recurrent allergic symptoms and frequent influenza infections. Modulating TDP-43–dependent pathways could, in principle, dampen inflammation while also reducing viral propagation.

Overall, the study reframes TDP-43 from a primarily neurobiological factor to a broader regulator of epithelial immunity. By linking allergen-driven inflammation to influenza replication, it offers a viral-science-relevant explanation for why some respiratory seasons are defined by both heightened allergies and viral burden.